Business Context and Reporting Period
Company: Nile Therapeutics, Inc. (formerly SMI Products, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2008
Business Stage: Development stage biopharmaceutical company focused on cardiovascular diseases.
Key Products: CD-NP (Phase II clinical studies for heart failure), 2NTX-99 (pre-clinical anti-atherothrombotic agent), and CU-NP (pre-clinical natriuretic peptide).
Key Financial Metrics
| Metric | Six Months Ended June 30, 2008 | Six Months Ended June 30, 2007 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(6,836,038) | $(2,237,825) |
| Loss Per Share (Basic & Diluted) | $(0.28) | $(0.16) |
| Cash and Cash Equivalents (End of Period) | $10,347,757 | $165,194 |
| Net Cash Used in Operating Activities | $(5,816,012) | $(1,803,270) |
| Total Assets | $11,189,610 | $17,089,328 (Dec 31, 2007) |
| Total Liabilities | $999,542 | $1,889,396 (Dec 31, 2007) |
Stock-Based Compensation: $1,184,145 for the six months ended June 30, 2008 (non-cash expense).
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses rose to $7,025,341 for the six months ended June 30, 2008, compared to $2,142,773 in the prior year period.
- R&D Expenses: Increased by approximately $3.4 million to $4,866,838. Drivers included a $1.2 million increase in manufacturing (CD-NP and 2NTX-99) and a $1.0 million increase in clinical development. A one-time $0.5 million expense was incurred for the CU-NP licensing agreement.
- G&A Expenses: Increased to $2,158,503 from $721,496, driven by higher personnel costs (including stock-based compensation) and professional fees related to public filing requirements.
- Interest Expense: Decreased significantly to $137 from $119,014 in the prior year due to the conversion of convertible promissory notes in September 2007.
- Liquidity: Cash balances decreased by approximately $5.9 million during the period due to operating burn, though the company maintains a positive cash position of over $10 million.
Guidance, Outlook, and Risks
- Capital Resources: Management believes current capital ($10.3 million) is sufficient to fund operations through the middle of 2009. Additional financing will be required thereafter to achieve profitability.
- Development Milestones:
- CD-NP: Phase IIa dose-escalation study initiated in July 2008. Phase Ib study completed; Phase II study expected to complete in H2 2008. A $400,000 milestone payment to Mayo was made in July 2008 upon dosing the first patient.
- 2NTX-99: Pre-clinical toxicology and manufacturing ongoing; IND filing and human testing targeted for 2009.
- CU-NP: Pre-clinical development initiated; early studies expected in H2 2008.
- Risks:
- Financing Risk: No assurance that additional equity or debt financing will be available on acceptable terms or at all.
- Development Risk: No product revenue expected for several years; success depends on FDA approval and clinical trial results.
- Licensing Obligations: Future milestone payments are due to Mayo and Dr. Casagrande upon achieving clinical and regulatory milestones.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "middle of 2009" funding estimate given the high burn rate (~$6M per six months).
- CD-NP Clinical Data: Monitor the results of the Phase IIa study initiated in July 2008 for safety and pharmacodynamic efficacy.
- Licensing Milestones: Track upcoming cash and equity obligations to Mayo Foundation and Dr. Casagrande tied to clinical trial initiation and regulatory approvals.
- Dilution: Assess the impact of potential future equity raises and existing warrant/option dilution (4.75 million potentially dilutive securities outstanding).
- Related Party Transactions: Review the terms of the lease termination and the warrants issued to Two River Group Holdings, LLC.